Both Akebia Therapeutics Inc. (NASDAQ:AKBA) and Xenetic Biosciences Inc. (NASDAQ:XBIO) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics Inc.	207.74M	4.04	143.59M	-1.28	0.00
Xenetic Biosciences Inc.	7.50M	2.63	1.22M	-0.12	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has Akebia Therapeutics Inc. and Xenetic Biosciences Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics Inc.	-69.12%	-45.4%	-17.5%
Xenetic Biosciences Inc.	-16.27%	-9.5%	-7%

Volatility and Risk

Akebia Therapeutics Inc. is 48.00% more volatile than S&P 500 because the stock has a beta of 1.48. Competitively, Xenetic Biosciences Inc.’s 130.00% volatility makes it more volatile than S&P 500, because of the 2.3 beta.

Liquidity

Akebia Therapeutics Inc.’s Current Ratio is 2.2 while its Quick Ratio is 2.2. On the competitive side is, Xenetic Biosciences Inc. which has a 1.7 Current Ratio and a 1.7 Quick Ratio. Akebia Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Xenetic Biosciences Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Akebia Therapeutics Inc. and Xenetic Biosciences Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Akebia Therapeutics Inc.	0	1	2	2.67
Xenetic Biosciences Inc.	0	0	0	0.00

Akebia Therapeutics Inc.’s upside potential currently stands at 118.85% and an $15.67 average price target.

Insider & Institutional Ownership

Akebia Therapeutics Inc. and Xenetic Biosciences Inc. has shares held by institutional investors as follows: 69.4% and 1.1%. Insiders held roughly 0.7% of Akebia Therapeutics Inc.’s shares. Competitively, insiders own roughly 64.63% of Xenetic Biosciences Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Akebia Therapeutics Inc.	-0.27%	35.03%	-8.6%	-10.25%	-48.4%	34.54%
Xenetic Biosciences Inc.	6.77%	18.82%	-27.54%	-23.26%	12.94%	34.76%

For the past year Akebia Therapeutics Inc. has weaker performance than Xenetic Biosciences Inc.

Summary

Xenetic Biosciences Inc. beats on 7 of the 11 factors Akebia Therapeutics Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.